Martin Linhult, Diamyd Medical

Image -

Martin Linhult, Diamyd Medical

go to media item
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.jpg
Size:
1032 x 576, 246 KB
Download

Topics

Contacts

Related content

  • Martin Linhult, CMC Lead at Diamyd Medical, and his team are focused on completing the installation of our manufacturing equipment and facilities in Umeå.

    Diamyd expands the team in Umeå for upscaled production of technical batches

    Diamyd Medical is expanding its workforce in Umeå, hiring individuals with key competencies for the production of technical batches of recombinant GAD65 protein. The company's biomanufacturing facility in Umeå is established for the production of Diamyd, currently being evaluated in a Phase III clinical trial for preserving insulin production.

Umeå Biotech Incubator Enter your email address to follow Umeå Biotech Incubator

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Umeå Biotech Incubator Check your inbox

Email sent to __email__. Click the link there to follow Umeå Biotech Incubator.

Okay